Doctor of Optometry Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Michael Belhumeur

Optometrist Latham, NY Doctor of Optometry

NPI 1467971200 CMS profile 3035835

767 Troy Schenectady Rd, Latham, NY 12110

Open in the dashboard

General payments

$4,126

157 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Belhumeur of Latham, NY is reported in the CMS Open Payments database as having received $4,126 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,710 99
2024 General $1,253 50
2023 General $164 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Belhumeur
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Michael Belhumeur were reported at $2,710. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Michael Belhumeur Optometrist median Middle half National median
2019 $0 $159 $67–$371 $163
2020 $0 $72 $29–$165 $114
2021 $0 $125 $46–$292 $132
2022 $0 $162 $66–$374 $149
2023 $164 $177 $72–$406 $160
2024 $1,253 $188 $77–$427 $164
2025 $2,710 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Tarsus Pharmaceuticals, Inc. $1,303 60 payments
  2. Bausch & Lomb Americas Inc. $1,208 36 payments
  3. AbbVie, Inc. $760 20 payments
  4. Oyster Point Pharma, Inc. $199 10 payments
  5. Sun Pharmaceutical Industries Inc. $119 5 payments
  6. Amgen Inc. $102 4 payments
  7. Dompe US, Inc. $75 4 payments
  8. Astellas Pharma US Inc $64 3 payments
  9. Alcon Vision LLC $60 3 payments
  10. Rayner Intraocular Lenses Limited $56 3 payments
  11. Other $179 9 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,126 157 payments
Products named General payments · program years 2023–2025
  1. XDEMVY $1,303 60 payments
  2. MIEBO $833 25 payments
  3. LUMIGAN $760 20 payments
  4. XIIDRA $577 12 payments
  5. VYZULTA $309 14 payments
  6. TYRVAYA $181 9 payments
  7. Ryzumvi $158 8 payments
  8. DURYSTA $125 1 payment
  9. XEN GLAUCOMA TREATMENT SYSTEM $125 1 payment
  10. Cequa $119 5 payments
  11. Other $830 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

279

Median for Optometry: 120

Drug cost

$7,211

Median for Optometry: $8,864

Branded share of claims

57.3%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Timolol Maleate Generic 20 $1,600
Tobramycin-Dexamethasone Tobramycin/Dexamethasone Brand 37 $1,542
Prednisolone Acetate Generic 35 $1,173
Erythromycin Erythromycin Base Brand 49 $1,020
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 74 $986
Latanoprost Generic 53 $784
Doxycycline Monohydrate Generic 11 $107

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LUMIGAN
  • AbbVie, Inc. $322
$322 — —
MIEBO
  • Bausch & Lomb Americas Inc. $236
$236 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $156
$156 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $110
$110 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $87
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record